2018 年 76 巻 4 号 p. 358-359
PROTACs (proteolysis-targeting chimeric molecules), which comprise a target protein ligand, an E3 ubiquitin ligase ligand and a linker, induce selective degradation of the target protein by recruiting the E3 ubiquitin ligase. This approach is attracting attention as an alternative of traditional inhibitor-based therapeutics by small molecules. This review briefly summarizes the development and advances of PROTACs.